A New On-Ramp for Postdocs: NIH's Academic Career Excellence (ACE) K32 Award
A bi-weekly newsletter where I share news, opinion, grant opportunities, success tools and tips on personal growth.
Oliver's Note
A New On-Ramp for Postdocs: NIH's Academic Career Excellence (ACE) K32 Award
NIH has posted a Notice of Funding Opportunityfor the Academic Career Excellence (ACE) Award, a K32 mechanism designed to support early-stage postdoctoral researchers (PAR-27-062).
The ACE Award provides salary and research development support for up to three years, intended for candidates who are within one year of beginning their postdoctoral position or within their first two years of postdoctoral training. Graduate student applicants need to have identified a postdoctoral mentor and submit their application from the prospective post-doc institution.
The K32 is positioned as an entry point into the K award ecosystem rather than a terminal mechanism. The expectation is that awardees will use the protected time to build toward more advanced career development awards — such as a K01, K08, or K99/R00 and eventually compete for independent research project funding like the R01.
It was developed by a team I led at NCI with the goal of creating an award that would allow early career scientists to experience grant writing at the start of their postdoc which is critical to making an informed career decision.
A few features of the ACE Award are worth highlighting for late-stage graduate students or early stage postdocs and their advisors:
No preliminary data required.Because applicants must be so early in their training, preliminary data is not expected. The emphasis instead is on innovative research ideas and a thoughtful mentorship and training plan. This lowers the barrier for early-career scientists who have not yet had the opportunity to generate substantial independent findings.
Budget is structured, not flexible.NIH contributes up to $80,000 per year toward the scholar's salary plus fringe benefits, and $30,000 per year for research development costs, covering items such as supplies, travel to meetings, tuition, and statistical services. Mentor and administrative salaries are not allowable. Indirect costs are reimbursed at 8% of modified total direct costs, a level typical of K awards.
Significant effort is required.Candidates must commit a minimum of 75% of their full-time professional effort to the career development program — equivalent to at least 9 person-months per year. Institutions and mentors must formally document their commitment to supporting this protected time.
Eligibility has clear boundaries.Individuals who have previously held major NIH research or career development awards — including R01, K01, K08, K23, and K99/R00 — are not eligible. However, those with smaller awards such as R03s, R21s, or institutional K12/KL2 appointments remain eligible. Notably, recipients of the F99/K00 Predoctoral to Postdoctoral Transition Award are explicitly excluded from applying as the K32 is very similar to the K00 phase.
Policy context matters.The NOFO includes standard language reflecting current administration priorities. Applications involving foreign subawards or subcontracts are deemed noncompliant under this opportunity — a policy now applied broadly across NIH awards. The notice also contains newer boilerplate language requiring that funded activities align with executive priorities around race, sex, immigration, and public safety, as well as a prohibition on harm reduction approaches in substance abuse-related applications. Applicants should read this section carefully before applying.
The participating institutes are:NCI, NIAID, NIBIB, NIDCR, and NINDS. Applications must fall within the scientific scope of one of these institutes. The first due date for new applications isOctober 12, 2026.
For postdoctoral scholars looking for early, structured career development support — particularly those in the early months of their training — the ACE Award is worth a close look. The no-preliminary-data requirement and the emphasis on mentorship planning make it accessible at a career stage when many funding options are still out of reach.
In Case You Missed It
NIH Floats a Cap on How Many Grants One PI Can Hold
On June 8, NIH issued a Request for Information (NOT-OD-26-086) proposing to cap the number of Research Project Grants a single investigator can hold simultaneously as PI or Multi-PI. The comment period closes August 3. Science reported on this as well.
NIH is asking for input on three possible thresholds — a cap of 2, 3, or 4 simultaneous RPGs — and estimates that depending on where the limit is set, between approximately $1.3 billion and $3.5 billion could be redirected to fund somewhere between 1,900 and 5,200 additional investigators.
The case NIH makes rests on a few claims: a body of research suggesting diminishing marginal returns as individual grant funding increases, and additional studies indicating that larger, more complex research teams tend to produce less innovative work and are associated with worse career outcomes for junior researchers. Proponents argue the change could broaden the geographic distribution of funding, strengthen the early- and mid-career workforce, and improve mentorship and research oversight.
This is not the first time NIH has gone down this road. A similar proposal emerged in 2017 under then-NIH Director Francis Collins, framed around a "Grant Support Index" that would have capped support at the equivalent of three standard R01 awards. That plan drew swift backlash — critics questioned the underlying research and raised concerns about disrupting productive labs — and NIH dropped it within a month.
The proposed implementation would be gradual: PIs above the cap could not accept a competing renewal without first relinquishing or transferring another grant, giving labs some runway to wind down work. A faster, harder one-year deadline is also on the table as an alternative, though NIH acknowledges this could be disruptive.
The RFI explicitly asks for input on unintended consequences and potential loopholes — a sign that NIH is approaching this carefully. The proposal is far from final, and community input will matter. Responses can be submitted electronically and may be shared publicly in unredacted form.
If you have a view on this — for, against, or somewhere in between — August 3 is the deadline to make it heard.
Growth Mindset
Significance and Innovation Are Not the Same Thing
Under NIH's new review framework,
Factor 1: Importance of the Research, encompasses both significance and innovation, but they're distinct concepts.
Significance asks: does this address an important gap?
Innovation asks: does it do so in a new way?
Crucially, a project doesn't have to be technically novel to be important. A study that finally answers a longstanding question using established methods can score well on significance.
Understand what each criterion is asking, and address both explicitly in your Significance and Innovation sections. If your problem is not significant and your approach not innovative no amount of well designed studies will get you the score you need.
The takeaway: Answering an old question well can be just as fundable as asking a new one - either way you need to make the case.
Success Tools
What the Modified NIH Peer Review Process Means for Your Application
If your application is going through NIH peer review in 2026, you're navigating a process that looks somewhat different from normal — and it's worth understanding why, and what it means for you.
The background. The 2025 federal government shutdown canceled more than 370 peer review meetings, impacting over 24,000 applications and throwing NIH's review calendar into serious disarray. NIH's Center for Scientific Review committed to completing three full rounds of peer review in fiscal year 2026, but doing so required temporary modifications to how applications are handled. Those modifications, first introduced for the January 2026 Advisory Council round, have now been extended.
What has changed. According to the recent notice the modifications will remain in place through the October 2026 Advisory Council. In most study section meetings, only 30–35% of applications will be discussed, down from the usual approximately 50%. Applications are sorted into three groups: the top third are discussed and considered for funding; the middle third are designated "competitive but not discussed" and remain eligible for funding; the lowest third are designated "not competitive and not discussed."
Summary statements have also changed. Rather than narrative paragraphs summarizing committee discussion, summaries now include a sentence on the degree of consensus in the committee vote, plus bullets listing the main score-driving points. Written critiques from the three assigned reviewers are still included for all applications, and discussed applications still receive an overall impact score.
What "competitive but not discussed" actually means. This designation is new to many applicants, and it can feel alarming — but it shouldn't automatically be read as a rejection. NIH created the middle-tier category specifically because it recognized that strong applications would inevitably fall below a narrower discussion cutoff. Applications in this tier can still be considered for funding. NIH clarified in April 2026 guidance that applications in the middle tier "were not overlooked" and may still be considered for funding based on programmatic priority, portfolio balance, or available funds. That said, it is a more competitive environment than usual — with fewer applications receiving full committee discussion, the stakes for a strong initial submission are higher.
What to do if your application lands in the middle tier.You can discuss your summary statement with appropriate program staff. Your program officer can offer perspective on whether your application aligns with institute priorities and whether it's worth pursuing a resubmission or a different strategy. They may request a 'response to reviewer' write up - I have seen that increasingly even for applications that score well. I believe that this information will flow into the now more substantial program/political review stage that is part of the stepping away from the payline announced a few weeks back.
The bottom line.These changes are currently presented as temporary and due to the unusual circumstances caused by the government shutdown. Personally, I think they are likely to become permanent, not least because government shutdowns are all too common. Furthermore, NIH has signaled that the modifications are working: by early 2026, 99.6% of summary statements for the January Council round were out, a remarkable recovery. And a clear indication that you can operate the peer review machine more efficiently, and so at lower cost.
Applicants should stay alert to whether further extensions beyond October 2026 are announced, and check their summary statements carefully for the new format when they arrive.
